Author:
Muñoz Gómez M.,Bisbe Vives E.,Basora Macaya M.,García Erce J.A.,Gómez Luque A.,Leal-Noval S.R.,Colomina M.J.,Comin Colet J.,Contreras Barbeta E.,Cuenca Espiérrez J.,Garcia de Lorenzo y Mateos A.,Gomollón García F.,Izuel Ramí M.,Moral García M.V.,Montoro Ronsano J.B.,Páramo Fernández J.A.,Pereira Saavedra A.,Quintana Diaz M.,Remacha Sevilla Á.,Salinas Argente R.,Sánchez Pérez C.,Tirado Anglés G.,Torrabadella de Reinoso P.
Reference98 articles.
1. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines;European Medicines Agency,2013
2. Nota informativa. Preparados de hierro de administración intravenosa y reacciones de hipersensibilidad: nuevas recomendaciones;Agencia Española de Medicamentos y Productos Sanitarios (AEMPS),2013
3. Annex III. Wording to be included in the Summary of Products Characteristics and Package Leaflet of tranexamic acid containing medicinal products listed in Annex I (as adopted by the CHMP on 19 June 2012);European Medicines Agency,2013
4. European Medicines Agency recommends lifting suspension of aprotinin;European Medicines Agency,2012
5. PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl starch,2014